CMS Covers Breakthrough Cancer Diagnostic More Broadly Than Originally Proposed

By John Wilkerson / March 16, 2018 at 7:38 PM
CMS granted broader coverage than it originally proposed for diagnostic laboratory tests using next generation sequencing, a breakthrough technology considered key to advancing personalized medicine that was approved following an unusual parallel review by CMS and FDA. CMS will not make labs study the diagnostics in return for covering them. The agency also expanded coverage to patients with relapsed, refractory or stage-three cancer and Medicare will pay for repeat testing when patients have new primary cancer diagnoses. FDA approved FoundationOne...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.